April 2024
Author Interview: Dr Jürgen Rech, 2024
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jürgen Rech, a Senior Physician at the Friedrich-Alexander University of Erlangen-Nürnberg, as they discuss his recent paper ‘Abatacept Inhibits Inflammation and Onset of Rheumatoid Arthritis in Individuals at High Risk (ARIAA): A Randomised, International, Multicentre, Double-blind, Placebo-controlled Trial.’
Discussing PsA: Long-term safety of ixekizumab & bimekizumab treatment in a TNFi-IR population
Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the long-term safety of ixekizumab as well as bimekizumab treatment in a TNFi-IR population.
March 2024
Discussing RA: March 2024
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that that add to the knowledge of common treatments relating to RA. In our first paper, Juergen Rech and colleagues present the results of the ARIAA study, which shows that abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. Our second paper is from Juergen Rech and colleagues, where they present the results of the ARIAA study which investigated whether abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. To access detailed summary slides for the papers discussed today, visit imidforum.com.
Discussing AxSpA: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publication, which compares patient-reported outcomes (PROs) and 24-month retention rates between patients with axSpA and PsA that were treated with secukinumab.
Discussing RA: February 2024
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that show the long-term safety and efficacy of JAK inhibitors, both of which have a study period of 6.5 years. In our first paper, Roberto Caporali and colleagues show long-term safety and efficacy data for baricitinib as an RA therapy. Our second paper is from Christina Charles-Schoeman and her colleagues, where they present long-term data on the effect of upadacitinib on laboratory parameters in people with RA. To access detailed summary slides for the papers discussed today, visit imidforum.com.
Discussing PsA: Clinical Response to Guselkumab & Sequential Lines of b/tsDMARDs
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the clinical response to guselkumab and the research surrounding sequential lines of b/tsDMARDs.